论文部分内容阅读
目的分析研究贝那普利联合罗格列酮治疗早期糖尿病肾病的临床疗效及安全性。方法将66例早期糖尿病肾病患者根据治疗适应证和家属意见分为两组,治疗组(33例)患者给予贝那普利联合罗格列酮治疗,对照组(33例)患者仅给予贝那普利治疗。观察两组的临床疗效和不良反应情况。结果治疗组总有效率明显高于对照组,两组比较差异有统计学意义(P<0.05)。两组患者在治疗后24h尿蛋白定量(Upr)、血清肌酐(Scr)、尿素氮(BUN)及空腹血糖(FPG)水平均较治疗前明显下降,且治疗组改善优于对照组(P<0.05)。结论贝那普利联合罗格列酮治疗早期糖尿病肾病具有较好的临床治疗效果,并为此病患者的治疗提供了一条安全、有效的新的治疗途径,值得临床推广使用。
Objective To analyze the clinical efficacy and safety of benazepril combined with rosiglitazone in the treatment of early diabetic nephropathy. Methods Sixty-six patients with early diabetic nephropathy were divided into two groups according to the indications of treatment and their relatives. The patients in the treatment group (33 cases) were treated with benazepril combined with rosiglitazone, while the control group (33 cases) Puli treatment. The clinical efficacy and adverse reactions of the two groups were observed. Results The total effective rate of the treatment group was significantly higher than that of the control group, the difference between the two groups was statistically significant (P <0.05). Urine proteinuria (Upr), serum creatinine (Scr), blood urea nitrogen (BUN) and fasting blood glucose (FPG) levels in both groups were significantly lower than those before treatment in 24 hours after treatment, and the treatment group improved better than the control group (P < 0.05). Conclusion The combination of benazepril and rosiglitazone in the treatment of early diabetic nephropathy has a good clinical therapeutic effect and provides a safe and effective new treatment for the treatment of this disease and is worthy of clinical promotion.